US Medicare coverage policy is supposed to be fenced off from considerations about the cost of a prescription drug (or other item or service). But the notion that the cost of Biogen, Inc. and Eisai Co., Ltd.’s Aduhelm was a factor in Medicare’s proposed national coverage policy for Alzheimer’s drugs continues to surface in the debate over the policy.
The Centers for Medicare and Medicaid Services released a draft national coverage determination 11 January proposing that Medicare coverage for...







